DDInter899 DDInter621
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Edoxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenyl salicylate
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Velpatasvir
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Edoxaban may lead to a major life threatening interaction when taken with Reteplase
Edoxaban may lead to a major life threatening interaction when taken with Velpatasvir